Sat, February 22, 2025
Fri, February 21, 2025
Thu, February 20, 2025
Wed, February 19, 2025
[ Wed, Feb 19th ]: sanews
Budget speech postponed
Tue, February 18, 2025
Mon, February 17, 2025
[ Mon, Feb 17th ]: Forbes
Ingmar Rentzhog
Sun, February 16, 2025
Sat, February 15, 2025

Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent

  Copy link into your clipboard //business-finance.news-articles.net/content/202 .. nt-saunders-no-deal-for-company-is-imminent.html
  Print publication without navigation Published in Business and Finance on by AOL
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb ( BLCO) chairman and CEO Brent Saunders won't be making in 2025. The one for his contact lens maker with a history dating back to the 1800s.

- Click to Lock Slider
The article from AOL Finance discusses Bausch + Lomb's CEO Brent Saunders, who has a history of dealmaking in the pharmaceutical industry. Saunders, known for his strategic acquisitions and divestitures, has led Bausch + Lomb through a significant transformation since taking the helm. Under his leadership, the company has focused on expanding its portfolio through acquisitions like the $1.75 billion purchase of XIIDRA from Novartis, aiming to strengthen its position in the eye care market. The article highlights Saunders' approach to business, emphasizing innovation, growth through strategic deals, and his vision for Bausch + Lomb to become a leader in eye health. It also touches on his past roles at companies like Allergan and his reputation for turning around businesses through bold corporate strategies.

Read the Full AOL Article at:
[ https://www.aol.com/finance/bausch-lombs-dealmaking-ceo-brent-135301653.html ]